AngioDynamics, Inc. ANGO

Company Overview

AngioDynamics, Inc. is a U.S.-based medical technology company that develops, manufactures, and markets minimally invasive medical devices used primarily in vascular access, oncology, and peripheral vascular disease treatment. The company operates within the broader medical device and interventional healthcare industries, with products designed for hospitals, outpatient centers, and physician practices. Its portfolio includes technologies for vascular access management, thrombus removal, tumor ablation, and circulation restoration procedures. Revenue is generated primarily through the sale of disposable medical devices and capital equipment systems used in image-guided and minimally invasive interventions.

The company’s principal business lines include the Med Tech and Med Device product categories, which encompass platforms such as the Auryon Atherectomy System, AlphaVac Mechanical Aspiration System, NanoKnife Irreversible Electroporation System, and vascular access products including ports, catheters, and PICCs. AngioDynamics has positioned itself around differentiated minimally invasive technologies, particularly in mechanical thrombectomy and irreversible electroporation for soft tissue ablation. Founded in 1988 and headquartered in Latham, New York, the company expanded through internal development and acquisitions, evolving from a vascular access device manufacturer into a diversified interventional medical technology company.

Business Operations

AngioDynamics organizes its operations primarily around two reportable product groupings: Med Tech and Med Device. The Med Tech segment includes higher-growth technology platforms such as the Auryon laser atherectomy system, the AlphaVac thrombectomy platform, and the NanoKnife ablation system. These technologies are used in peripheral artery disease treatment, pulmonary embolism intervention, and oncology procedures. The Med Device segment includes vascular access products, drainage products, and other established intervention tools used in acute care settings. The company generates recurring revenue through disposable products used alongside capital systems installed at healthcare facilities.

Operations are concentrated in the United States, though the company also maintains international distribution activities across parts of Europe, Canada, Asia-Pacific, and selected emerging markets through direct sales teams and third-party distributors. AngioDynamics controls intellectual property associated with laser atherectomy, irreversible electroporation, and aspiration thrombectomy technologies, supported by patent portfolios and proprietary system designs. The company has historically expanded through acquisitions and technology licensing, including the acquisition of Eximo Medical Ltd., which strengthened its atherectomy capabilities through laser-based vascular intervention technologies.

Strategic Position & Investments

AngioDynamics has focused its strategic direction on transitioning toward higher-growth and higher-margin interventional platforms while reducing dependence on lower-growth legacy product categories. Management has emphasized investment in thrombectomy, peripheral arterial disease treatment, and oncology technologies, particularly through commercialization of the AlphaVac and Auryon systems. The company has also pursued clinical evidence generation and physician adoption initiatives intended to support broader reimbursement and utilization across hospital systems.

A major strategic investment was the acquisition of Eximo Medical Ltd., which provided the foundation for the Auryon Atherectomy System and expanded the company’s position in peripheral vascular intervention. AngioDynamics has also invested in the continued development of the NanoKnife platform, which uses irreversible electroporation technology for tissue ablation while aiming to preserve surrounding structures. The company’s broader strategy has included restructuring initiatives and portfolio optimization efforts intended to improve operating efficiency and focus resources on differentiated growth technologies. Public filings and investor communications consistently identify minimally invasive intervention and image-guided therapies as core long-term growth priorities.

Geographic Footprint

AngioDynamics is headquartered in Latham, New York, and maintains operational and commercial activities primarily in North America, which represents the majority of company revenue. The company also serves customers in parts of Europe, Asia-Pacific, Latin America, and the Middle East through a combination of direct commercial infrastructure and distributor relationships. Manufacturing, research, and administrative functions are concentrated largely within the United States.

Its international market presence remains smaller relative to major global medical device competitors, but the company has expanded access to selected technologies through regulatory approvals and distributor networks outside the United States. Strategic growth efforts have included increasing physician adoption of interventional platforms in developed healthcare markets and selective international commercialization of thrombectomy and vascular intervention technologies.

Leadership & Governance

AngioDynamics is led by a management team with experience across medical devices, healthcare operations, and interventional technologies. Corporate governance is overseen by a board of directors responsible for strategic oversight, capital allocation, and compliance with public company reporting standards under SEC filings and related regulatory requirements. Leadership communications have emphasized innovation in minimally invasive therapy, disciplined operational execution, and expansion of clinically differentiated technologies.

Key executives include:

• James C. Clemmer – President and Chief Executive Officer
• Stephen A. Trowbridge – Executive Vice President and Chief Financial Officer
• Laura M. Piccinini – Senior Vice President, General Counsel and Corporate Secretary
• Joseph M. Buehler – Senior Vice President and General Manager, Med Tech
• Chad Campbell – Senior Vice President, Global Manufacturing and Operations

Management strategy has consistently focused on accelerating growth in higher-value technology platforms, improving gross margin performance, and strengthening the company’s position in minimally invasive vascular and oncology interventions.